Aclaris Therapeutics Inc. (ACRS)
1.71
0.11 (6.87%)
At close: Mar 24, 2025, 3:59 PM
1.70
-0.04%
After-hours: Mar 24, 2025, 04:02 PM EDT
Aclaris Therapeutics Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
| Revenue | 18.72M | 31.25M | 29.75M | 6.76M | 6.48M | 4.23M | 10.09M | 1.68M | n/a | n/a | n/a | n/a |
| Cost of Revenue | 2.79M | 18.08M | 11.96M | 4.71M | 5.13M | 4.05M | 6.85M | 1.21M | 120K | 90K | n/a | n/a |
| Gross Profit | 15.93M | 13.17M | 17.79M | 2.05M | 1.35M | 172K | 3.24M | 476K | -120K | -90K | n/a | n/a |
| Operating Income | -141.93M | -97.36M | -85.15M | -65.38M | -50.91M | -111.06M | -135.41M | -72.42M | -48.57M | -20.67M | -8.53M | -5.26M |
| Interest Income | 7.95M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 104K | 16K | 21K |
| Pretax Income | -132.06M | -88.85M | -86.91M | -90.86M | -51.34M | -113.54M | -132.74M | -70.35M | -48.08M | -20.56M | -8.52M | -5.24M |
| Net Income | -132.06M | -88.48M | -88.66M | -114.28M | -51.15M | -142.85M | -132.74M | -68.52M | -48.08M | -20.56M | -8.52M | -5.24M |
| Selling & General & Admin | 22.2M | 31.1M | 25.13M | 23.62M | 20.53M | 27.83M | 75.65M | 33.11M | 15.09M | 5.33M | 2.03M | 1.77M |
| Research & Development | 33.59M | 98.38M | 77.81M | 43.81M | 31.73M | 64.9M | 63.01M | 39.79M | 33.48M | 15.34M | 6.51M | 3.49M |
| Other Expenses | 102.07M | -18.96M | 2.95M | -1.14M | -424K | -2.48M | 2.68M | 2.07M | 488K | n/a | n/a | n/a |
| Operating Expenses | 157.86M | 110.53M | 102.95M | 67.43M | 52.26M | 92.73M | 138.66M | 72.9M | 48.57M | 20.67M | 8.53M | 5.26M |
| Interest Expense | n/a | n/a | 4.7M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | 283K | 671K | 48M | 85K | 3.29M | n/a | n/a | n/a |
| Cost & Expenses | 160.65M | 128.61M | 114.91M | 72.14M | 57.39M | 96.78M | 145.5M | 74.11M | 48.57M | 20.67M | 8.53M | 5.26M |
| Income Tax | n/a | -367K | 1.75M | 23.42M | -182K | 29.31M | 2.68M | -1.83M | -120K | -90K | n/a | n/a |
| Shares Outstanding (Basic) | 77.3M | 69.81M | 65.21M | 56.73M | 42.54M | 41.32M | 32.91M | 28.1M | 21.42M | 6.11M | 10.66M | 10.66M |
| Shares Outstanding (Diluted) | 77.3M | 69.81M | 65.21M | 56.73M | 42.54M | 41.32M | 32.91M | 28.1M | 21.42M | 6.11M | 10.66M | 10.66M |
| EPS (Basic) | -1.71 | -1.27 | -1.36 | -2.01 | -1.2 | -3.46 | -4.03 | -2.44 | -2.25 | -3.37 | -0.8 | -0.49 |
| EPS (Diluted) | -1.71 | -1.27 | -1.36 | -2.01 | -1.2 | -3.46 | -4.03 | -2.44 | -2.25 | -3.37 | -0.8 | -0.49 |
| EBITDA | -51.72M | -117.56M | -84.36M | -65.06M | -48.2M | -90.84M | -80.78M | -53.45M | -48.57M | -20.67M | -8.52M | -5.25M |
| Depreciation & Amortization | 807K | 863K | 797K | 923K | 1.32M | 1.59M | 1.32M | 402K | 120K | 90K | 12K | 11K |